Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study
Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. High...
Gespeichert in:
| Veröffentlicht in: | Journal of viral hepatitis 2021-01, Vol.28 (1), p.205-208 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 208 |
|---|---|
| container_issue | 1 |
| container_start_page | 205 |
| container_title | Journal of viral hepatitis |
| container_volume | 28 |
| creator | Beudeker, Boris J. B. Groothuismink, Zwier M. A. Man, Robert A. Witjes, Caroline D. M. Eijk, Annemiek A. Boonstra, Andre Sonneveld, Milan J. |
| description | Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC. |
| doi_str_mv | 10.1111/jvh.13394 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756674</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2470493376</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4434-f2f9726dac23b9f7d3083653f5720a7bb00d584f591bd7ff5afe77409273eccf3</originalsourceid><addsrcrecordid>eNp1kstu1DAUQCMEoqWw4AeQJTawSOvYTjxhgUTLY0CV2EC3luNcTzxy4qkfM5odn8Bv8Rt8CU6nVICEN34dn3uvdYviaYVPqzzO1tvhtKK0ZfeK44o2dUkWLb0_r2tS4hqzo-JRCGuMK0rq6mFxRMmiaVtCjosfS9jIaKIJ6Bwp5-Hnt-8erIzQIzlFs4IJWdiCDWjjoTcqIg8qeQ-TmlntAVBIfmu20iIzodkGUwxoZ-KAludXGZIhOGVunCC93eejEOUK0DAHdwqsTVZ6pKRXZnKjfJWDhGSzRXs3IonepqgGZN20ym8j-BFpZ63b5V3aoBBTv39cPNDSBnhyO58UX9-_-3KxLC8_f_h48eayVIxRVmqiW06aXipCu1bznuJF_jKqa06w5F2HcV8vmK7bquu51rXUwDnDLeEUlNL0pHh98G5SN0KvcrFeWrHxZpR-L5w04u-byQxi5baC87ppOMuCF7cC764ThChGE-Y_kBO4FARhtG0IrxjN6PN_0LVLfsrlZYpj1lLKm0y9PFDKuxA86LtkKizmBhG5QcRNg2T22Z_Z35G_OyIDZwdgZyzs_28Sn66WB-UvqEXRYA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2470493376</pqid></control><display><type>article</type><title>Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study</title><source>Wiley Journals</source><creator>Beudeker, Boris J. B. ; Groothuismink, Zwier M. A. ; Man, Robert A. ; Witjes, Caroline D. M. ; Eijk, Annemiek A. ; Boonstra, Andre ; Sonneveld, Milan J.</creator><creatorcontrib>Beudeker, Boris J. B. ; Groothuismink, Zwier M. A. ; Man, Robert A. ; Witjes, Caroline D. M. ; Eijk, Annemiek A. ; Boonstra, Andre ; Sonneveld, Milan J.</creatorcontrib><description>Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC.</description><identifier>ISSN: 1352-0504</identifier><identifier>EISSN: 1365-2893</identifier><identifier>DOI: 10.1111/jvh.13394</identifier><identifier>PMID: 32869922</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Antigens ; HBcrAg ; Hepatitis B ; Hepatocellular carcinoma ; Liver cancer ; Liver diseases ; Medical prognosis ; Short Communication ; Survival</subject><ispartof>Journal of viral hepatitis, 2021-01, Vol.28 (1), p.205-208</ispartof><rights>2020 The Authors. published by John Wiley & Sons Ltd</rights><rights>2020 The Authors. Journal of Viral Hepatitis published by John Wiley & Sons Ltd.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4434-f2f9726dac23b9f7d3083653f5720a7bb00d584f591bd7ff5afe77409273eccf3</citedby><cites>FETCH-LOGICAL-c4434-f2f9726dac23b9f7d3083653f5720a7bb00d584f591bd7ff5afe77409273eccf3</cites><orcidid>0000-0001-8607-1616 ; 0000-0002-9253-563X ; 0000-0003-3830-6366</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjvh.13394$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjvh.13394$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32869922$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beudeker, Boris J. B.</creatorcontrib><creatorcontrib>Groothuismink, Zwier M. A.</creatorcontrib><creatorcontrib>Man, Robert A.</creatorcontrib><creatorcontrib>Witjes, Caroline D. M.</creatorcontrib><creatorcontrib>Eijk, Annemiek A.</creatorcontrib><creatorcontrib>Boonstra, Andre</creatorcontrib><creatorcontrib>Sonneveld, Milan J.</creatorcontrib><title>Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study</title><title>Journal of viral hepatitis</title><addtitle>J Viral Hepat</addtitle><description>Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC.</description><subject>Antigens</subject><subject>HBcrAg</subject><subject>Hepatitis B</subject><subject>Hepatocellular carcinoma</subject><subject>Liver cancer</subject><subject>Liver diseases</subject><subject>Medical prognosis</subject><subject>Short Communication</subject><subject>Survival</subject><issn>1352-0504</issn><issn>1365-2893</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><recordid>eNp1kstu1DAUQCMEoqWw4AeQJTawSOvYTjxhgUTLY0CV2EC3luNcTzxy4qkfM5odn8Bv8Rt8CU6nVICEN34dn3uvdYviaYVPqzzO1tvhtKK0ZfeK44o2dUkWLb0_r2tS4hqzo-JRCGuMK0rq6mFxRMmiaVtCjosfS9jIaKIJ6Bwp5-Hnt-8erIzQIzlFs4IJWdiCDWjjoTcqIg8qeQ-TmlntAVBIfmu20iIzodkGUwxoZ-KAludXGZIhOGVunCC93eejEOUK0DAHdwqsTVZ6pKRXZnKjfJWDhGSzRXs3IonepqgGZN20ym8j-BFpZ63b5V3aoBBTv39cPNDSBnhyO58UX9-_-3KxLC8_f_h48eayVIxRVmqiW06aXipCu1bznuJF_jKqa06w5F2HcV8vmK7bquu51rXUwDnDLeEUlNL0pHh98G5SN0KvcrFeWrHxZpR-L5w04u-byQxi5baC87ppOMuCF7cC764ThChGE-Y_kBO4FARhtG0IrxjN6PN_0LVLfsrlZYpj1lLKm0y9PFDKuxA86LtkKizmBhG5QcRNg2T22Z_Z35G_OyIDZwdgZyzs_28Sn66WB-UvqEXRYA</recordid><startdate>202101</startdate><enddate>202101</enddate><creator>Beudeker, Boris J. B.</creator><creator>Groothuismink, Zwier M. A.</creator><creator>Man, Robert A.</creator><creator>Witjes, Caroline D. M.</creator><creator>Eijk, Annemiek A.</creator><creator>Boonstra, Andre</creator><creator>Sonneveld, Milan J.</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-8607-1616</orcidid><orcidid>https://orcid.org/0000-0002-9253-563X</orcidid><orcidid>https://orcid.org/0000-0003-3830-6366</orcidid></search><sort><creationdate>202101</creationdate><title>Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study</title><author>Beudeker, Boris J. B. ; Groothuismink, Zwier M. A. ; Man, Robert A. ; Witjes, Caroline D. M. ; Eijk, Annemiek A. ; Boonstra, Andre ; Sonneveld, Milan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4434-f2f9726dac23b9f7d3083653f5720a7bb00d584f591bd7ff5afe77409273eccf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antigens</topic><topic>HBcrAg</topic><topic>Hepatitis B</topic><topic>Hepatocellular carcinoma</topic><topic>Liver cancer</topic><topic>Liver diseases</topic><topic>Medical prognosis</topic><topic>Short Communication</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beudeker, Boris J. B.</creatorcontrib><creatorcontrib>Groothuismink, Zwier M. A.</creatorcontrib><creatorcontrib>Man, Robert A.</creatorcontrib><creatorcontrib>Witjes, Caroline D. M.</creatorcontrib><creatorcontrib>Eijk, Annemiek A.</creatorcontrib><creatorcontrib>Boonstra, Andre</creatorcontrib><creatorcontrib>Sonneveld, Milan J.</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of viral hepatitis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beudeker, Boris J. B.</au><au>Groothuismink, Zwier M. A.</au><au>Man, Robert A.</au><au>Witjes, Caroline D. M.</au><au>Eijk, Annemiek A.</au><au>Boonstra, Andre</au><au>Sonneveld, Milan J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study</atitle><jtitle>Journal of viral hepatitis</jtitle><addtitle>J Viral Hepat</addtitle><date>2021-01</date><risdate>2021</risdate><volume>28</volume><issue>1</issue><spage>205</spage><epage>208</epage><pages>205-208</pages><issn>1352-0504</issn><eissn>1365-2893</eissn><abstract>Prognosis of hepatitis B (HBV)‐associated hepatocellular carcinoma (HCC) is poor due to high rates of HCC recurrence and progression of underlying liver disease. We studied whether serum hepatitis B core‐related antigen (HBcrAg) levels could predict HCC recurrence and outcome in HBV associated. Higher HBcrAg levels at HCC diagnosis were independently associated with reduced overall and recurrence‐free survival in patients with early, but not advanced, stage HCC.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>32869922</pmid><doi>10.1111/jvh.13394</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-8607-1616</orcidid><orcidid>https://orcid.org/0000-0002-9253-563X</orcidid><orcidid>https://orcid.org/0000-0003-3830-6366</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-0504 |
| ispartof | Journal of viral hepatitis, 2021-01, Vol.28 (1), p.205-208 |
| issn | 1352-0504 1365-2893 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7756674 |
| source | Wiley Journals |
| subjects | Antigens HBcrAg Hepatitis B Hepatocellular carcinoma Liver cancer Liver diseases Medical prognosis Short Communication Survival |
| title | Hepatitis B core‐related antigen levels predict recurrence‐free survival in patients with HBV‐associated early‐stage hepatocellular carcinoma: results from a Dutch long‐term follow‐up study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T09%3A19%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20core%E2%80%90related%20antigen%20levels%20predict%20recurrence%E2%80%90free%20survival%20in%20patients%20with%20HBV%E2%80%90associated%20early%E2%80%90stage%20hepatocellular%20carcinoma:%20results%20from%20a%20Dutch%20long%E2%80%90term%20follow%E2%80%90up%20study&rft.jtitle=Journal%20of%20viral%20hepatitis&rft.au=Beudeker,%20Boris%20J.%20B.&rft.date=2021-01&rft.volume=28&rft.issue=1&rft.spage=205&rft.epage=208&rft.pages=205-208&rft.issn=1352-0504&rft.eissn=1365-2893&rft_id=info:doi/10.1111/jvh.13394&rft_dat=%3Cproquest_pubme%3E2470493376%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2470493376&rft_id=info:pmid/32869922&rfr_iscdi=true |